Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (68 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.W | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Health Canada
View:
Post by 99942Apophis on Oct 23, 2023 9:15am

Health Canada

Today's approval by Health Canada was perhaps overlooked by many of us because we were so focused on the US FDA , however to me and everyone I can truly say we are beyond pleased with this news release. In a short while I believe we will also hear the same positive approval coming from the FDA, Today's news has removed the pins & needles from my anticipation,  great news and a big thank you to all those at Theralase who made this happen.
Comment by riverrrow on Oct 23, 2023 9:59am
HEALTH CANADA!   Yes, HEALTH CANADA!  This has nothing to do with the FDA or BTD submission.  In fact, I would like to be very optimistic and suggest that in a back handed way Health Canada has just approved Ruvidar as a treatment option for NMIBC.  My limited experience with various government agencies is that while quite often you don't get what you want on paper or ...more  
Comment by riverrrow on Oct 23, 2023 10:02am
As a follow up this is also a very good indication that Health Canada recognizes the safety aspects of Ruvidar and that multiple treatments have a good prospect of raising the CR.
Comment by 99942Apophis on Oct 23, 2023 10:12am
yes riverrrow you are correct, after reading it again I realize my error. 
Comment by CAinPlap on Oct 23, 2023 10:21am
My take on the trial amendment is that the original trial protocol called for 2 treatments. As some patients were chosing not to get the 2nd treatment, the trial was tainted as they were not following the original trial protocol. This fixes that.
Comment by Longholder99 on Oct 23, 2023 10:22am
I agree.  In giving no objection to additional treatments as required Health Canada has given the green light quietly AND has said it without saying it....that Ruvidar can and does remove cancerous cells from the bladder safely.  Just sometimes you have to do it a few times and not necessarily on a date driven schedule.  Very big news if you think about it. 
Comment by Rumpl3StiltSkin on Oct 23, 2023 10:31am
OK, so will the FDA do the same?  :-)
Comment by skys1 on Oct 23, 2023 2:46pm
This developement also means many patients getting additional treatments. additional treatments means more revenue and therefore more profits. TLT keeps getting more valuable to a prospective suitor.
Comment by menoalittle on Oct 23, 2023 2:55pm
>> prospective suitor Can't say as I would object much to a takeover deal from Merck at this point. As long as it's not a cash deal.  10 shares of TLT for 1 of MRK? (would probably be quite the bargain from MRK's perspective...) 
Comment by Infinity on Oct 23, 2023 3:10pm
That would be dream come true proposal. Potentialy a perfect combination to supplement Ruvidar to their already approved Keytruda.  Make Keytruda more effective..
Comment by chry200030 on Oct 23, 2023 3:16pm
might be a bit too cheap. 5 for 1 would be about right..
Comment by skys1 on Oct 23, 2023 3:34pm
Menoalittle, re-prospective suitor, your proposed TLT 10 to MRK 1? That's roughly $10 p/sh. That's interesting as my valuation of TLT is currently in the 3 to 4 $ billion range which is roughly $10 p/sh. However, consider all the new prospective hires that TLT is planning most of which are experienced professional clinical trial specialists for their planned new trials. How would that ...more  
Comment by BudFoxx2020 on Oct 23, 2023 4:00pm
Since comedy hour has started.  Here we go.  Spin, spin, spin.  The promoters burying the news that BTD is delayed again.  Lololololol.  Once again best way to distract.  Talk about billions and billions while share price is at 0.26 cents.  Lolololololol.  Like I said just come here for the endless laugh and entertainment provided by these promoters here ...more  
Comment by Oden6570 on Oct 23, 2023 4:19pm
And I will drink to that !
Comment by 99942Apophis on Oct 23, 2023 4:20pm
skys1,  I would be very interested in seeing your calculations to support your $10 a share price. In the past my calculations were laid out for anyone to criticize or support,  what PE ratio are you using? My lowest share price at the time was $20 however that was only for NMIBC in Canada & US. 
Comment by Paradise818 on Oct 23, 2023 2:56pm
How much will the patent for Ruvidar and updates be worth once approval received and we also start treating other cancers?  Sherri is going to be one rich girl. 
Comment by skys1 on Oct 23, 2023 11:55am
I agree riverrow, this is a very positive news release and will provide an additional aspect to TLT in it's trial results. How some on this Board can create some negativity related to it makes no sense. It just confirms SF's opinion of the negativity on this board. 
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

View the Presentation

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 68 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250